FR17C1020I2 - Fsh recombinante comprenant la sialylation alpha 2,3 et alpha 2,6 - Google Patents

Fsh recombinante comprenant la sialylation alpha 2,3 et alpha 2,6

Info

Publication number
FR17C1020I2
FR17C1020I2 FR17C1020C FR17C1020C FR17C1020I2 FR 17C1020 I2 FR17C1020 I2 FR 17C1020I2 FR 17C1020 C FR17C1020 C FR 17C1020C FR 17C1020 C FR17C1020 C FR 17C1020C FR 17C1020 I2 FR17C1020 I2 FR 17C1020I2
Authority
FR
France
Prior art keywords
alpha
sialylation
recombinant fsh
fsh including
including alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR17C1020C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Ferring BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR17C1020(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring BV filed Critical Ferring BV
Application granted granted Critical
Publication of FR17C1020I2 publication Critical patent/FR17C1020I2/fr
Publication of FR17C1020I1 publication Critical patent/FR17C1020I1/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
FR17C1020C 2008-04-16 2017-06-06 Fsh recombinante comprenant la sialylation alpha 2,3 et alpha 2,6 Active FR17C1020I2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25
EP09733497.3A EP2268666B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
EP14178729.1A EP2808340B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
EP13193214.7A EP2722339A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (2)

Publication Number Publication Date
FR17C1020I2 true FR17C1020I2 (fr) 2020-04-10
FR17C1020I1 FR17C1020I1 (enExample) 2020-04-10

Family

ID=39717519

Family Applications (3)

Application Number Title Priority Date Filing Date
FR17C1020C Active FR17C1020I2 (fr) 2008-04-16 2017-06-06 Fsh recombinante comprenant la sialylation alpha 2,3 et alpha 2,6
FR25C1003C Active FR25C1003I1 (fr) 2008-04-16 2025-01-16 Fsh recombinante comprenant la sialylation alpha 2,3 et alpha 2,6
FR25C1025C Active FR25C1025I1 (fr) 2008-04-16 2025-07-02 Fsh recombinante comprenant la sialylation alpha 2,3 et alpha 2,6

Family Applications After (2)

Application Number Title Priority Date Filing Date
FR25C1003C Active FR25C1003I1 (fr) 2008-04-16 2025-01-16 Fsh recombinante comprenant la sialylation alpha 2,3 et alpha 2,6
FR25C1025C Active FR25C1025I1 (fr) 2008-04-16 2025-07-02 Fsh recombinante comprenant la sialylation alpha 2,3 et alpha 2,6

Country Status (29)

Country Link
US (6) US8951967B2 (enExample)
EP (7) EP3144318B1 (enExample)
JP (7) JP2011519359A (enExample)
KR (5) KR20170110741A (enExample)
CN (3) CN102066414A (enExample)
AR (1) AR071479A1 (enExample)
AU (5) AU2009237479B2 (enExample)
BR (1) BRPI0910461B8 (enExample)
CA (1) CA2725257A1 (enExample)
CY (1) CY1115413T1 (enExample)
DK (6) DK3045471T3 (enExample)
ES (5) ES2629392T3 (enExample)
FI (4) FI4015527T3 (enExample)
FR (3) FR17C1020I2 (enExample)
HR (5) HRP20250313T1 (enExample)
HU (9) HUE071059T2 (enExample)
IL (2) IL208538A (enExample)
LT (8) LT3045471T (enExample)
MX (3) MX2010011343A (enExample)
NO (4) NO2017025I1 (enExample)
NZ (1) NZ588381A (enExample)
PL (6) PL3144318T3 (enExample)
PT (6) PT3098234T (enExample)
RU (3) RU2682270C2 (enExample)
SA (1) SA109300228B1 (enExample)
SI (6) SI2268666T1 (enExample)
TW (1) TWI488640B (enExample)
WO (1) WO2009127826A1 (enExample)
ZA (1) ZA201007373B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) * 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
HUE025514T2 (en) 2010-09-29 2016-02-29 Ferring Bv Preparation for use in treating infertility
KR101898302B1 (ko) 2010-10-15 2018-09-13 제이씨알 파마 가부시키가이샤 당사슬의 비환원 말단이 만노오스 잔기인 당 단백질의 제조 방법
US9757469B2 (en) 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
JP6279466B2 (ja) * 2012-04-27 2018-02-14 Ｊｃｒファーマ株式会社 新規な発現ベクター
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) * 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
JP2018500934A (ja) * 2014-12-22 2018-01-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｍｐ依存性シアリダーゼ活性
ES2879838T3 (es) 2015-04-17 2021-11-23 Ferring Bv Composición que comprende FSH para el tratamiento de la esterilidad
CN107709350A (zh) * 2015-06-26 2018-02-16 辉凌公司 纯化和/或病毒灭活的方法
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
ES2989511T3 (es) 2017-09-01 2024-11-26 Ferring Bv Composición para la estimulación ovárica controlada
EP4534145A3 (en) 2018-04-30 2025-07-02 Ferring B.V. Composition for controlled ovarian stimulation
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
US20220380785A1 (en) * 2019-11-01 2022-12-01 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
EP4504236A1 (en) 2022-04-01 2025-02-12 Ferring B.V. Mixed protocol for treatment of infertility
JP2025516966A (ja) 2022-05-26 2025-05-30 フェリング ベスローテン フェンノートシャップ 男性の不妊症の治療のための組成物及び方法
EP4551244A1 (en) 2022-07-08 2025-05-14 Ferring B.V. Compositions and methods for intrauterine insemination (iui)
TW202504578A (zh) 2023-07-20 2025-02-01 荷蘭商輝凌責任有限公司 緩釋載藥微粒

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
EP1445322B2 (en) 1995-06-15 2012-06-06 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
DE69823046T2 (de) 1997-01-16 2005-03-31 Neose Technologies, Inc. Praktische in vitro sialylierung von rekombinanten glykpproteinen
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
WO2000067778A1 (en) 1999-05-07 2000-11-16 Applied Research Systems Ars Holding N.V. Gonadotrophins
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
AU2002340562B2 (en) * 2001-10-22 2008-10-23 Merck Serono Sa Compositions of FSH with high sialylation degree and their use for the preparation of medicaments
ATE542904T1 (de) 2001-10-29 2012-02-15 Crucell Holland Bv Verfahren und mittel zur herstellung von proteinen mit vorbestimmten posttranslationalen modifikationen
KR100979025B1 (ko) 2001-12-07 2010-08-30 크루셀 홀란드 비.브이. 바이러스, 바이러스 단리물 및 백신의 생산
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
US20080015142A1 (en) * 2003-12-03 2008-01-17 Defrees Shawn Glycopegylated Follicle Stimulating Hormone
CA2554968C (en) 2004-02-04 2012-03-27 Centre National De La Recherche Scientifique Process for screening glycoform-specific antibodies
JP4913604B2 (ja) 2004-02-13 2012-04-11 グリコトープ ゲーエムベーハー 高活性糖タンパク質−製造条件、及びその効率的製造方法
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
TWI604850B (zh) 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016575A1 (en) 2010-08-03 2012-02-09 King Saud University Stoma coat
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
HUE025514T2 (en) 2010-09-29 2016-02-29 Ferring Bv Preparation for use in treating infertility
US9757469B2 (en) 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
EP3131571A1 (en) 2014-04-18 2017-02-22 Glycotope GmbH Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone

Also Published As

Publication number Publication date
ES2468318T3 (es) 2014-06-16
EP2268666B1 (en) 2014-03-12
LT3045471T (lt) 2017-07-10
EP3144318A1 (en) 2017-03-22
SA109300228B1 (ar) 2014-04-08
EP3045471B1 (en) 2017-03-29
PL3045471T3 (pl) 2017-10-31
RU2537268C2 (ru) 2014-12-27
HUE033830T2 (en) 2018-01-29
LT2808340T (lt) 2016-11-10
CY1115413T1 (el) 2017-01-04
EP2722339A1 (en) 2014-04-23
TW200948378A (en) 2009-12-01
HUS2500029I1 (hu) 2025-07-28
KR20190092608A (ko) 2019-08-07
HRP20241187T1 (hr) 2024-12-06
AU2017225020B2 (en) 2019-11-14
US9546204B2 (en) 2017-01-17
EP3144318B1 (en) 2020-09-23
US20150065695A1 (en) 2015-03-05
KR20160056960A (ko) 2016-05-20
SI2268666T1 (sl) 2014-07-31
JP7316905B2 (ja) 2023-07-28
SI3098234T1 (sl) 2024-10-30
AU2014203277B2 (en) 2017-04-06
RU2682270C2 (ru) 2019-03-18
CN105906703A (zh) 2016-08-31
US20110105398A1 (en) 2011-05-05
AU2017204259B2 (en) 2017-08-17
US11952407B2 (en) 2024-04-09
CA2725257A1 (en) 2009-10-22
LTPA2017029I1 (lt) 2017-10-10
MX348622B (es) 2017-06-22
FR25C1003I1 (fr) 2025-02-28
NO2017050I1 (no) 2017-09-28
KR20180095140A (ko) 2018-08-24
HUS1700036I1 (hu) 2017-10-30
SI4015527T1 (sl) 2025-05-30
PL2268666T3 (pl) 2014-08-29
FI3098234T3 (fi) 2024-10-31
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
HUE030652T2 (en) 2017-05-29
HUS2500008I1 (hu) 2025-02-28
JP6762916B2 (ja) 2020-09-30
RU2014141994A (ru) 2016-05-10
PT4015527T (pt) 2025-04-10
FR17C1020I1 (enExample) 2020-04-10
BRPI0910461A8 (pt) 2018-10-16
RU2014141994A3 (enExample) 2018-05-28
PT2268666E (pt) 2014-06-25
RU2745557C3 (ru) 2021-12-10
NO2025032I1 (no) 2025-07-14
HUS1700025I1 (hu) 2017-06-28
HK1199039A1 (en) 2015-06-19
FI4015527T3 (fi) 2025-04-29
LT3098234T (lt) 2024-09-10
PT3144318T (pt) 2020-11-04
ES2629392T3 (es) 2017-08-09
BRPI0910461B8 (pt) 2021-05-25
US9771407B2 (en) 2017-09-26
ES2989729T3 (es) 2024-11-27
AU2017225020A1 (en) 2017-09-28
NO2025006I1 (no) 2025-01-16
RU2745557C1 (ru) 2021-03-29
JP6486310B2 (ja) 2019-03-20
FR25C1025I1 (fr) 2025-09-19
NZ588381A (en) 2012-05-25
AU2014203277A1 (en) 2014-07-24
EP2268666A1 (en) 2011-01-05
JP2011519359A (ja) 2011-07-07
RU2010141908A (ru) 2012-05-27
EP3098234B1 (en) 2024-07-31
BRPI0910461B1 (pt) 2021-02-23
DK3144318T3 (da) 2020-12-07
EP4015527B1 (en) 2025-01-22
EP2808340A1 (en) 2014-12-03
LT4015527T (lt) 2025-04-10
JP2015120696A (ja) 2015-07-02
LTPA2025505I1 (enExample) 2025-02-10
EP4015527A1 (en) 2022-06-22
DK2808340T3 (en) 2016-12-05
HUE068565T2 (hu) 2025-01-28
US20160347811A1 (en) 2016-12-01
EP3098234A1 (en) 2016-11-30
FIC20250003I1 (fi) 2025-01-15
DK2268666T3 (da) 2014-05-12
AU2009237479B2 (en) 2014-05-15
HRP20161520T1 (hr) 2016-12-30
AU2017204258B2 (en) 2017-08-17
KR102108377B1 (ko) 2020-05-08
HRP20250313T1 (hr) 2025-05-09
HK1146284A1 (en) 2011-05-20
KR20110005863A (ko) 2011-01-19
ZA201007373B (en) 2011-06-29
KR20170110741A (ko) 2017-10-11
CN102066414A (zh) 2011-05-18
PT3098234T (pt) 2024-10-21
JP2020040956A (ja) 2020-03-19
AU2017204258A1 (en) 2017-07-20
AU2009237479A1 (en) 2009-10-22
KR101622944B1 (ko) 2016-05-23
JP2017060476A (ja) 2017-03-30
CN105906702A (zh) 2016-08-31
EP3045471A1 (en) 2016-07-20
HUS1700024I1 (hu) 2017-06-28
US20180079794A1 (en) 2018-03-22
PL3144318T3 (pl) 2021-02-08
BRPI0910461A2 (pt) 2018-03-27
IL208538A (en) 2014-03-31
JP2022031652A (ja) 2022-02-22
EP2808340B1 (en) 2016-08-17
US20210332099A1 (en) 2021-10-28
TWI488640B (zh) 2015-06-21
AU2017204259A1 (en) 2017-07-20
US10995128B2 (en) 2021-05-04
NO2017025I1 (no) 2017-06-06
ES3023526T3 (en) 2025-06-02
AU2014203277C1 (en) 2017-07-27
JP2018021037A (ja) 2018-02-08
DK4015527T3 (da) 2025-04-14
SI3045471T1 (sl) 2017-07-31
SI3144318T1 (sl) 2020-12-31
FIC20250025I1 (fi) 2025-07-11
LTPA2017018I1 (lt) 2017-06-26
HUE071059T2 (hu) 2025-07-28
HRP20170958T1 (hr) 2017-09-22
WO2009127826A1 (en) 2009-10-22
IL230571A (en) 2015-11-30
LTPA2025525I1 (enExample) 2025-07-25
PL2808340T3 (pl) 2017-02-28
US20240327487A1 (en) 2024-10-03
MX355457B (es) 2018-04-19
PT3045471T (pt) 2017-06-14
PL3098234T3 (pl) 2025-01-07
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
PT2808340T (pt) 2016-11-21
DK3045471T3 (en) 2017-06-26
JP2024038000A (ja) 2024-03-19
SI2808340T1 (sl) 2016-12-30
AR071479A1 (es) 2010-06-23
IL208538A0 (en) 2010-12-30
DK3098234T3 (da) 2024-10-21
HUE030652T4 (en) 2017-09-28
US8951967B2 (en) 2015-02-10

Similar Documents

Publication Publication Date Title
FR25C1025I1 (fr) Fsh recombinante comprenant la sialylation alpha 2,3 et alpha 2,6
BRPI0815773A2 (pt) composto, e, medicamento.
ITVE20060045A1 (it) Dispositivo riscaldatore per calzature, guanti e simili.
Meroni et al. CRAWDAD dataset unimi/pmtr (v. 2008-12-01)
JP2012513655A5 (enExample)
BRPI0923402A2 (pt) Peptídeos c10rf59 e vacinas incluindo os mesmos.
Ochi Taxonomic studies on the coprophagous scarab-beetles of Borneo: a review of Scarabaeinae and Coprinae (Coleoptera, Scarabaeidae)
梁栋 et al. 湖南 新金矿床地质特征及控矿因素分析
এস এম মনির হোসেন আবু ইসহাকের গল্পের সমাজবাস্তবতা
Ara ঢোঁড়াই চরিতমানস'-এ নিম্নবর্গের জীবন
আবু জাফর মোহাম্মদ সালেহ et al. টেনিসনের ভাবনায় মৃত্যু প্রসঙ্গ
CN301071626S (zh) 客车(eq6750p3g)
TH113134S (th) เก้าอี้สำหรับใช้ประกอบส้วม
ES1059941Y (es) Rodapie o zocalo calefactor.
TH111365S (th) เก้าอี้
TH111364S (th) เก้าอี้
TH106413S (th) เก้าอี้
TH106414S (th) เก้าอี้
TH111363S (th) เก้าอี้
TH106419S (th) เก้าอี้
TH111883S (th) เก้าอี้
TH106751S (th) เก้าอี้
TH106412S (th) เก้าอี้
SE0801220L (sv) Hurry 1.3
IT1396447B1 (it) Dispositivo per la cottura in forno di arrosticini, spiedini e simili.